Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Germline-targeting-(GT) is a promising strategy to activate rare broadly neutralizing antibody (bnAb)-producing B cells against HIV, but induction of such responses in outbred animals has not been achieved. Using antibody-guided structure-based design, we engineered a germline-targeting trimer immunogen Q23-APEX-GT2 that primes diverse V2-apex bnAb precursors. Q23-APEX-GT2 efficiently activated V2-apex-specific B cells in humanized knock-in mice and consistently elicited immunofocused antibody responses in rhesus macaques, priming multiple long CDRH3-loop bnAb-B cell lineages. Monoclonal antibodies from immunized macaques exhibited broad heterologous HIV trimer binding and cross-neutralization. Atomic-level structural studies confirmed precise epitope targeting and revealed CDRH3-paratope configurations that mirrored those of human V2-apex bnAbs. This study provides proof-of-principle for successful priming and maturation of authentic V2-apex bnAb precursors in outbred macaques, underscoring the potential of V2-apex-targeted vaccines.

HIGHLIGHTS

  • Engineered Q23-APEX-GT2 trimer to stimulate diverse V2-apex bnAb B cell precursors

  • Q23-APEX-GT2 primed rare V2-apex bnAb B cells in mice and outbred rhesus macaques

  • Q23-APEX-GT2 elicited immunofocused antibody responses and diverse V2-apex B cell lineages with desirable long-CDRH3 paratope properties

  • Q23-APEX-GT2 alone induced V2-apex antibodies with broad HIV trimer binding and modest neutralization breadth

  • Structural analysis confirmed bnAb site targeting, mirroring human and rhesus V2-apex bnAbs

Article activity feed